Trial · NCT03028740
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage and No Worsening of Steatohepatitis on Liver Histology at Month 12 | Placebo | 25.5 | 95% Confidence Interval 21.5 to 29.9 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage and No Worsening of Steatohepatitis on Liver Histology at Month 12 | Cenicriviroc 150 mg | 22.3 | 95% Confidence Interval 19.6 to 25.2 | percentage of participants | |
| Time to First Occurrence of Adjudicated Events in the Full Study Cohort | Placebo | NA | 95% Confidence Interval NA to NA | days | |
| Time to First Occurrence of Adjudicated Events in the Full Study Cohort | Cenicriviroc 150 mg | NA | 95% Confidence Interval NA to NA | days | |
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages and No Worsening of Steatohepatitis on Liver Histology at Month 12 | Placebo | 8.3 | 95% Confidence Interval 6.0 to 11.3 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages and No Worsening of Steatohepatitis on Liver Histology at Month 12 | Cenicriviroc 150 mg | 6.6 | 95% Confidence Interval 5.1 to 8.5 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage Regardless of Effect on Steatohepatitis at Month 12 | Placebo | 33.3 | 95% Confidence Interval 28.6 to 38.4 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage Regardless of Effect on Steatohepatitis at Month 12 | Cenicriviroc 150 mg | 30.6 | 95% Confidence Interval 27.3 to 34.2 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages Regardless of Effect on Steatohepatitis at Month 12 | Placebo | 10.3 | percentage of participants | ||
| Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages Regardless of Effect on Steatohepatitis at Month 12 | Cenicriviroc 150 mg | 8.8 | percentage of participants | ||
| Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage and No Worsening of Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Placebo | 25.0 | 95% Confidence Interval 21.2 to 29.2 | percentage of participants | |
| Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage and No Worsening of Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Cenicriviroc 150 mg | 22.0 | 95% Confidence Interval 19.4 to 24.8 | percentage of participants | |
| Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage Regardless of Effect on Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Drug: Placebo | 33.2 | 95% Confidence Interval 28.7 to 38.2 | percentage of participants | |
| Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage Regardless of Effect on Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Drug: Cenicriviroc 150 mg | 30.5 | 95% Confidence Interval 27.3 to 33.9 | percentage of participants | |
| Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages and No Worsening of Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Placebo | 8.3 | 95% Confidence Interval 5.9 to 11.1 | percentage of participants | |
| Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages and No Worsening of Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Cenicriviroc 150 mg | 6.8 | 95% Confidence Interval 5.2 to 8.6 | percentage of participants | |
| Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages Regardless of Effect on Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Placebo | 9.9 | percentage of participants | ||
| Percentage of Participants With Improvement in Fibrosis by at Least 2 Stages Regardless of Effect on Steatohepatitis on Liver Biopsy at Month 12 in the Full Study Cohort | Cenicriviroc 150 mg | 8.9 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03028740/results